GI Partners announced the completion of its acquisition of the Contract Development and Manufacturing Organization and Cell Solutions businesses from Charles River Laboratories, forming a new standalone company called Rose BioSolutions.
Rose BioSolutions will operate as an independent advanced therapy manufacturing company focused on end-to-end services across the cell and gene therapy sector. The business combines CDMO development and manufacturing capabilities with Cell Solutions’ cellular materials platform.
The company’s offerings span plasmid DNA, viral vector manufacturing, cell therapy production, and cell supply operations designed to support research and therapeutic development programs.
According to GI Partners, the transaction positions Rose Bio to pursue a growth strategy centered exclusively on cell and gene therapy development and manufacturing while investing in innovation, operational improvements, and expanded capabilities.
Rose Bio will operate facilities in Rockville, Maryland; Memphis, Tennessee; Northridge, California; and Keele, United Kingdom.
GI Partners said the company will focus on delivering integrated manufacturing and development solutions through its “R.O.S.E.” framework, representing Reliable, Outcome-driven, Scalable, and Excellent client service standards.
The investment firm stated that Rose Bio is designed to address growing demand for comprehensive development and manufacturing support across the advanced therapies market.
GI Partners, founded in 2001, manages more than $49 billion across private equity, real estate, and data infrastructure investment strategies.
KEY QUOTES:
“Our vision for the launch of Rose Bio was to create an independent company dedicated to cell and gene therapy development and manufacturing, building on the scientific expertise and strong operational track record of the CDMO and Cell Solutions businesses.”
“Rose Bio fills a gap in the market for a truly end-to-end partner where every step, from starting materials to finished therapy, is part of a single, comprehensive offering.”
“We understand the complexities of the life sciences sector, an industry where we have deep experience, and are well positioned to support the long-term, sustained growth of this platform.”
“We are excited to invest in the infrastructure and world-class team to support the company’s consistent execution and accelerate innovation.”
Dave Kreter, Managing Director And Head Of Healthcare Investments, GI Partners
“Demand for advanced therapies continues to grow, underscoring the importance of having a trusted partner at all stages of the research, development, and manufacturing processes and making our solutions and expertise more important than ever before.”
“By bringing together one of the industry’s broadest portfolios of cellular starting materials with world-class manufacturing capabilities across cell therapies, viral vectors, and plasmid DNA, we are well positioned to deliver comprehensive solutions with the reliability, quality, and scale our customers need to move programs forward and bring therapies to patients.”
Ahmad Hussin, Global Head Of CDMO And Chief Operating Officer, Rose Bio
